Journal article
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
-
Bucher P
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Erdmann T
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
-
Grondona P
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Xu W
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
-
Schmitt A
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Schürch C
Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
-
Zapukhlyak M
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
-
Schönfeld C
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Serfling E
Department of Molecular Pathology, University of Würzburg, Würzburg, Germany.
-
Kramer D
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Grau M
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
-
Klener P
Institute of Pathological Physiology, First Faculty of Medicine, and.
-
Lengerke C
Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
-
Schulze-Osthoff K
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
-
Lenz G
Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
-
Hailfinger S
Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
Show more…
English
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.
-
Language
-
-
Open access status
-
closed
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/231741
Statistics
Document views: 27
File downloads: